FDA requires NAION vision-loss warning on all GLP-1 receptor agonist labels

Þessi færsla er sýnd á ensku þar til þýðing hennar hefur verið uppfærð.

The FDA is requiring makers of all GLP-1 receptor agonist medicines to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that causes sudden, painless vision loss in one eye and can be permanent, to the Warnings and Precautions section of their labels. In an FDA analysis of 126 randomized trials with 134,253 patients, NAION occurred at 6.4 cases per 100,000 person-years with GLP-1 drugs versus 3.8 with a placebo or other glucose-lowering medicine. In an FDA cohort study of adults with type 2 diabetes, risk was higher than with DPP-4 inhibitors (hazard ratio 1.43) but not significantly different from SGLT-2 inhibitors (hazard ratio 1.19).

Heimild

  1. 01FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition(opnar heimildina í nýjum flipa) U.S. Food and Drug Administration

Peptíð sem koma við sögu

  1. SamþykktSemaglutideGLP-1 viðtakaörvi31
  2. SamþykktTirzepatideTvívirkur örvi GIP- og GLP-1 viðtaka39
  3. SamþykktLiraglutideGLP-1 viðtakaörvi31
  4. SamþykktDulaglutideGLP-1 viðtakaörvi (Fc samrunaprótein)31
  5. SamþykktExenatideGLP-1 viðtakaörvi39